- Home
- CVCO vs APLS Comparison
CVCO vs APLS Comparison
Compare CVCO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVCO
- APLS
- Stock Information
- Founded
- CVCO 1965
- APLS 2009
- Country
- CVCO United States
- APLS United States
- Employees
- CVCO N/A
- APLS N/A
- Industry
- CVCO Homebuilding
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CVCO Consumer Discretionary
- APLS Health Care
- Exchange
- CVCO Nasdaq
- APLS Nasdaq
- Market Cap
- CVCO 3.8B
- APLS 3.7B
- IPO Year
- CVCO N/A
- APLS 2017
- Fundamental
- Price
- CVCO $515.86
- APLS $28.78
- Analyst Decision
- CVCO Buy
- APLS Buy
- Analyst Count
- CVCO 2
- APLS 18
- Target Price
- CVCO $487.50
- APLS $46.71
- AVG Volume (30 Days)
- CVCO 59.3K
- APLS 2.0M
- Earning Date
- CVCO 01-30-2025
- APLS 02-25-2025
- Dividend Yield
- CVCO N/A
- APLS N/A
- EPS Growth
- CVCO 2.67
- APLS N/A
- EPS
- CVCO 20.25
- APLS N/A
- Revenue
- CVCO $1,927,218,000.00
- APLS $715,216,000.00
- Revenue This Year
- CVCO $10.88
- APLS $96.72
- Revenue Next Year
- CVCO $7.24
- APLS $12.30
- P/E Ratio
- CVCO $25.65
- APLS N/A
- Revenue Growth
- CVCO 4.11
- APLS 162.10
- 52 Week Low
- CVCO $331.08
- APLS $24.34
- 52 Week High
- CVCO $544.08
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- CVCO 70.15
- APLS 41.49
- Support Level
- CVCO $465.19
- APLS $27.91
- Resistance Level
- CVCO $526.50
- APLS $30.60
- Average True Range (ATR)
- CVCO 14.08
- APLS 1.13
- MACD
- CVCO 6.25
- APLS -0.08
- Stochastic Oscillator
- CVCO 83.22
- APLS 26.69
About CVCO Cavco Industries Inc. When Issued
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.